Recombinant antibodies are highly specific detection probes in research, diagnostics, and
have emerged over the last two decades as the fastest growing class of therapeutic proteins …

Plants are now gaining widespread acceptance as a general platform for the large-scale
production of recombinant proteins. The first plant-derived recombinant pharmaceutical …

Today, plant biotechnology relies on two processes for delivery and expression of
heterologous genes in plants: stable genetic transformation and transient infection with viral …

The concept of using plants to produce high‐value pharmaceuticals such as vaccines is 20
years old this year and is only now on the brink of realisation as an established technology …

Plants are a promising expression system for the production of heterologous proteins,
especially therapeutic proteins. Currently the majority of therapeutic proteins are produced …

Plant viral vectors delivered by Agrobacterium are the basis of several manufacturing
processes that are currently in use for producing a wide range of proteins for multiple …

In the last few years, plants have become an increasingly attractive platform for recombinant
protein production. This builds on two decades of research, starting with transgenic …

Global demand for recombinant proteins has steadily accelerated for the last 20 years.
These recombinant proteins have a wide range of important applications, including vaccines …

Plants have been proposed as an attractive alternative for pharmaceutical protein
production to current mammalian or microbial cell‐based systems. Eukaryotic protein …

Plant viral vectors are being successfully developed and exploited for the industrial-scale
expression of heterologous proteins and as a research tool for studies of gene expression …